

SAO WEEKLY EQUITY REPORT

R2AR34 Weekly Report

Ultragenyx Pharmaceutical Inc.

R2AR34 closed the latest completed week at 17.08 BRL. The 4-week return is - and the 12-week return is -. The trend backdrop is inactive, with activity pressure at 0.00.

Field	Value	Field	Value
Week ending	03 Jul 2026	Evidence rating	Caution
Evidence score	36	Currency	BRL
Exchange	SAO	Country	BR
Sector	Healthcare	Industry	Biotechnology
Market cap	1.7B	Report page	Available online

OPEN 15.90 BRL weekly open	HIGH 18.02 BRL weekly high	LOW 15.76 BRL weekly low	CLOSE 17.08 BRL weekly close	VOLUME 4.7K latest week	TREND 0.0% 0 of 4 weeks active
--	--	--	--	---	--

Company brief

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvida (burosumab), an...

EXECUTIVE READ

What matters now

Top-level conclusion, primary support, and the main restraint in the current weekly setup.

Conclusion

The strongest supporting evidence is next-week expectancy: Next-week expectancy is negative with a 0.00% historical one-week setup read. The main constraint is indicator analysis: Latest 12-week confirmation: trend 0/4, activity pressure 0/4, relative leadership 0/4. The combined read is defensive, so risk control and evidence of stabilization matter more than headline upside.


Read	Pillar	Score	Detail
Primary support	Next-Week Expectancy	Negative 0.00%	Next-week expectancy is negative with a 0.00% historical one-week setup read.
Main restraint	Indicator analysis	10/100	Latest 12-week confirmation: trend 0/4, activity pressure 0/4, relative leadership 0/4.

WEEKLY TAPE

Price, Trend Line, and Fair Value

Price path, range position, trend distance, Fair Value gap, and return windows.

52-week price path



Black: weekly close. Green: Trend Line. Grey: Fair Value.

TREND DISTANCE - price vs Trend Line	FAIR GAP 28.8% price vs Fair Value	DRAWDOWN -5.2% from 52-week high	RANGE 84.7% 52-week range	VOLUME 4.0x vs 13-week average
--	--	--	---	--

Pillar	Score	Read	Detail
1W	42.5%	Positive	
4W	-	Neutral	
12W	-	Neutral	
26W	-	Neutral	
52W	-	Neutral	

SETUP

Composite setup scorecard

Current setup pillars scored on the same 0-100 scale.

Composite radar



Pillar	Score	Read	Detail
Trend	0	Negative	
Momentum	50	Neutral	
Activity Pressure	50	Neutral	
Relative Leadership	50	Neutral	
Next-Week Expectancy	50	Neutral	
Volume	100	Positive	
Smart Money	26	Negative	
Risk Control	8	Negative	

Current evidence clusters


Pillar	Score	Read	Detail
Price follow-through	42.5%	Positive	Latest completed week; four-week move -.
Indicator stack	0/50	Negative	Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop	Active	Positive	The trend backdrop defines the current weekly regime.
Patient Capital	Quiet	Neutral	Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy	Negative 0.00%	Negative	Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment	48/100	Neutral	8 relevant articles in the latest sentiment read.

INDICATOR EVIDENCE

Activity pressure, trend confirmation, and next-week expectancy


The current 12-week confirmation window, activity-pressure read, and historical one-week setup read.

Activity pressure path



Latest 0.20 | 12-week average 0.20

Next-week expectancy path



Current Negative 0.00% historical one-week setup read

Pillar	Score	Read	Detail
Trend active	0/4	Negative	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	0/4	Negative	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	0/4	Negative	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.20	Negative	Current proprietary activity-pressure read.
Buy signals	0	Neutral	Accumulation signal count in the latest 12 weeks.
Reversal markers	1	Negative	1 reversal markers

Area	Latest read	Detail
Activity pressure	0.00	Four-week pressure change -.
Relative leadership	-	Four-week relative leadership change -.
Smart money activity	38	No recent accumulation markers. 1 reversal markers.

PARTICIPATION AND RISK

Volume, volatility, and return shape

Participation confirms attention; return shape frames the current risk profile.

Area	Latest	Baseline	Read
Volume	4.7K	13W 1.2K 52W 1.2K	4.0x vs 13-week average
Volatility	20.0%	52W 20.0%	1 upside weeks / 0 downside weeks
Average move	42.5%	-	Downside breadth 0.0%

Pillar	Score	Read	Detail
Participation	4.0x	Positive	Latest volume versus the 13-week average.
Baseline	1.2K	Neutral	13-week average volume.
One-year base	1.2K	Neutral	52-week average volume.
Recent vol	20.0%	Neutral	13-week weekly-return volatility.
Base vol	20.0%	Neutral	52-week weekly-return volatility.
Up/down split	1/0	Positive	Count of positive and negative weeks in the 52-week window.
Average skew	42.5% / -	Neutral	Average positive week versus average negative week.

EXTERNAL CONFIRMATION

Options, sentiment, events, insiders, and research flow

Supporting evidence that can confirm, challenge, or qualify the weekly tape.

Pillar	Score	Read	Detail
Weekly tape	38/100	Negative	Trend, activity pressure, participation, and risk combine to a 38/100 tape read.
Indicator analysis	10/100	Negative	Latest 12-week confirmation: trend 0/4, activity pressure 0/4, relative leadership 0/4.
Next-Week Expectancy	Negative 0.00%	Neutral	Next-week expectancy is negative with a 0.00% historical one-week setup read.
Factors	50/100	Neutral	No published factor snapshot is available yet.
Patient Capital	Quiet	Neutral	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Sentiment	48/100	Neutral	Weighted news tone is neutral across 8 relevant articles.
Insiders	50/100	Neutral	No recent insider transaction evidence is stored.
Earnings	50/100	Neutral	No stored earnings event is currently attached to this ticker.

Evidence	Current read	Detail
Sentiment	48/100	8 relevant articles. Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

SECTOR CONTEXT

Sector and industry pulse

Group context helps separate stock-specific movement from broader rotation.

Group	Scope	Peers	4W rank	Trend breadth
Sector	BR Healthcare	81	- of 81	23.5%
Industry	BR Biotechnology	13	- of 13	7.7%

Sector leaders

Peer	Exchange	1W	4W	Trend
M1RN34	SAO	22.0%	69.7%	On
T1CH34	SAO	1.6%	38.8%	Off
T2DH34	SAO	9.3%	28.7%	On
C1AH34	SAO	0.1%	25.0%	Off
I1NC34	SAO	1.7%	24.7%	Off

Industry leaders

Peer	Exchange	1W	4W	Trend
M1RN34	SAO	22.0%	69.7%	On
T1CH34	SAO	1.6%	38.8%	Off
I1NC34	SAO	1.7%	24.7%	Off
A1RG34	SAO	6.9%	22.4%	Off
VRTX34	SAO	13.7%	20.3%	Off

ACTIONABLE READ

Opportunities, risks, and watch points

Evidence clusters to monitor as the next weekly bar develops.

Opportunity signals

- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.

Risk signals

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 0.00% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- 1 reversal markers appear in the recent smart-money tape.

Watch next

- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

EVIDENCE TRAIL

Recent completed weeks

Recent weekly bars behind the report.

Week	Close	Move	Trend	Activity	Volume
03 Jul	17.08 BRL	42.5%	Off	0.00	4.7K
26 Jun	11.99 BRL	0.0%	Off	-	0
19 Jun	11.99 BRL	0.0%	Off	-	0
12 Jun	11.99 BRL	-	Off	-	38

Report footer

Copyright 2026 Sharemaestro. All rights reserved.

[sharemaestro.com](#) | [Open this report online](#) | [Full disclaimer](#)

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.